Immunogenicity and safety of Tetraxim versus local DTP + IPV.

Trial Profile

Immunogenicity and safety of Tetraxim versus local DTP + IPV.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Mar 2013

At a glance

  • Drugs DTaP poliovirus vaccine; DTaP vaccine; Poliovirus vaccine
  • Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors Sanofi
  • Most Recent Events

    • 16 Feb 2010 Actual number of patients added to 442 as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Actual end date added [1 Jul 2008] as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top